Sentence examples for cost-effectiveness figure from inspiring English sources

Using this criteria, 88 patients were selected - ranging from 9-19 per department - to determine cost-effectiveness (figure 2).

To satisfy the standard of cost-effectiveness, Figure  3 suggests that the cost of PCV-7 should be reduced to at least 35.1 or 21.5% of the base-case value with or without herd immunity, respectively.

Services are also very cost-effective, achieving an average cost per life year saved, after allowance for future health care savings, of £438 [ 2], which is over 50 times below the English National Institute of Health and Clinical Excellence's benchmark cost-effectiveness figure of £30,000 [ 3].

Some GP-commissioners have doubts about the utility and benefits, finding the cost-effectiveness figures rather thin.

An unrealistically low assessment of the emission reduction potential of a certain technology could result in inflated cost-effectiveness figures.

ASP showed that, although the impact of the GP intervention was modest, the cost-effectiveness figures were impressive.

Warren and colleagues (2004) assessed the economic evaluation presented with the original NICE submission of insulin glargine and published revised cost-effectiveness figures.

Thirdly, the cost-effectiveness figures estimated also confirmed the findings of other studies (e.g. [ 54, 55]) namely that for the same disease, it was more attractive from an efficiency point of view to have the health problem taken care of at the lowest level of the referral system as possible.

The following key steps are required: The first step for contextualizing WHO-CHOICE cost-effectiveness figures involves the specification and definition of interventions to be included in the analysis, including a clear description of the target population, population-level coverage and, where applicable, the treatment regimen.

Therefore, azacitidine was considered a cost-effective option in the Spanish setting due to the fact that the ICER value was situated under the €50,000/QALY cost-effectiveness threshold (Figure 5). Figure 5 Cost-effectiveness acceptability curves: Azacitidine vs. BSC and Azacitidine vs. LDC.

Furthermore, the ICER value was €28,891/LY gained and €34,673/QALY gained and was located under the €50,000/QALY cost-effectiveness threshold (Figure 2).